Optimising business key for pharma in downturn, says CourtSquareGroup

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology

US strategic consultants CourtSquareGroup say that while optimisation of operations is key for the drug industry, companies risk losing the business knowledge required to undertake such action in the scramble to cut costs in the global downturn.

Keith Parent and Andy Sontag from CourtSquare told in-PharmaTechnologist about the emerging trend among pharmaceutical companies to seek specialist business process optimisation (BPO) expertise.

As pharmaceutical manufacturing processes become more complex, identifying critical steps and where improvements can be made is becoming increasingly complex.

Andy and Keith explain that this complexity is driving demand for BPO and predict that the market will continue to expand for the foreseeable future.

Related news

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us

Products

View more

Webinars